Matching-adjusted indirect comparison of efficacy outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma

被引：0
|
作者：
Goldschmidt, H. [1 ]
Shah, N. [2 ]
Ayers, D. [3 ]
Davies, F. [4 ]
Cope, S. [3 ]
Mojebi, A. [3 ]
Dhanda, D. [5 ]
Hari, P. [6 ]
Patel, P. [5 ]
Huang, L. [5 ]
Hege, K. [5 ]
Dhanasiri, S. [7 ]
机构：
[1] Univ Hosp Heidelberg, Internal Med & Natl Ctr Tumor Dis NCT 5, Heidelberg, Germany
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] PRECISIONheor, Vancouver, BC, Canada
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Med Coll Wisconsin, Div Hematol & Oncol, Dept Med, Brookfield, WI USA
[7] Celgene Int Sarl, Boudry, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep256
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [21] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Connarn, Jamie
    Patel, Payal
    Huang, Liping
    Campbell, Timothy Brandon
    Hege, Kristen
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [23] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
    Albert, Oriol
    Jesus, San-Miguel
    Ankit, Kansagra
    Deepu, Madduri
    Nina, Shah
    Philippe, Moreau
    Ibrahim, Yakoub-Agha
    Michel, Delforge
    Michele, Cavo
    Hermann, Einsele
    Hartmut, Goldschmidt
    Katja, Weisel
    Alessandro, Rambaldi
    Donna, Reece
    Paula, Rodriguez-Otero
    Fabio, Petrocca
    Jamie, Connarn N.
    Payal, Patel
    Huang Liping
    Timothy, Campbell B.
    Kristen, Hege
    Nikhil, Munshi C.
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
  • [24] Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
    Einsele, H.
    Shah, N.
    Delforge, M.
    San-Miguel, J. F.
    Bertin, K. B.
    Tahir, M. J.
    Lewis, H. B.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Dhanda, D.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 206 - 208
  • [25] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
    Einsele, Hermann
    Berdeja, Jesus
    Raje, Noopur
    Siegel, David
    Lin, Yi
    Anderson, Larry, Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy
    Jagannath, Sundar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
  • [26] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [27] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
    Einsele, H.
    Berdeja, J.
    Raje, N. S.
    Siegel, D. S.
    Lin, Y.
    Anderson, L. D., Jr.
    Rodriguez-Otero, P.
    Manier, S.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Sanford, J.
    Wang, J.
    Campbell, T. B.
    Jagannath, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
  • [28] KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Green, Damian J.
    Jagannath, Sundar
    Lonial, Sagar
    Gipson, Adrianna
    Caia, Andrea
    Martin, Nathan
    Yang, Zhihong
    Pittari, Gianfranco
    Mateos, Maria-Victoria
    BLOOD, 2021, 138
  • [29] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [30] Single-center experience with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma
    Sanoyan, D. Akhoundova
    Bacher, U.
    Kronig, M. -N.
    Seipel, K.
    Daskalakis, M.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 64S - 64S
12345